

FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
 (use as many sheets as necessary)

Application Number	10/551,094
Filing Date	
First Named Inventor	Nicholas S. Bodor
Examiner Name	
Attorney Docket No.	1033935-000020

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	4,383,992		Lipari	05-17-1983
	6,239,118	B1	Schatz et al.	05-29-2001
	5,424,296		Saven et al.	06-13-1995
	5,510,336		Saven et al.	04-23-1996
	5,506,214		Beutler	04-09-1996
	4,659,696		Hirai et al.	04-21-1987
	3,459,731		Gramera et al.	08-05-1969
	4,478,995		Shinoda et al.	10-23-1984
	5,310,732		Carson et al.	05-10-1994
	5,401,724		Beutler	03-28-1995
	5,106,837		Carson et al.	04-21-1992
	4,497,803		Harada et al.	02-05-1985
	6,194,395	B1	Schultz et al.	02-27-2001
	6,407,079	B1	Müller et al.	06-18-2002
	4,870,060		Müller	09-26-1989
	4,727,064		Pitha	02-23-1988
	4,596,795		Pitha	06-24-1986
	4,764,604		Müller	08-16-1988
	4,226,848		Nagai et al.	10-07-1980
	4,250,163		Nagai et al.	02-10-1981
	4,535,152		Szejtli et al.	08-13-1985
	5,401,724		Beutler	03-28-1995

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPR	Abstract	Cited in Spec
	0 197 571	A2	EP	10-15-1986							X
	90/12035	A1	WO	10-18-1990							X
	31 18 218	A1	DE	04-22-1982						X	X
	33 17 064	A1	DE	11-15-1984						X	X
	2 189 245	A	UK	10-21-1987							X
	0 149 197	B1	EP	07-24-1985	X						X
	0 094 157	A1	EP	11-16-1983							X

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Tarasiuk et al., "Stability of 2-Chloro-2'-Deoxyadenosine at Various pH and Temperature", Archivum Immunologiae et Therapiae Experimentalis, Vol. 42, pp. 13-15, 1994, published by Birkhauser Publishers Ltd., Basel, Switzerland

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.W.S.

FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
 (use as many sheets as necessary)

Application Number	10/551,094
Filing Date	
First Named Inventor	Nicholas S. Bodor
Examiner Name	
Attorney Docket No.	1033935-000020

Sheet 2 of 2

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Romine et al., "A Double-Blind, Placebo-Controlled, Randomized Trial of Cladribine in Relapsing-Remitting Multiple Sclerosis", Proceedings of the Association of American Physicians, Vol. 111, No. 1, pp. 35-44, 1999, published by Blackwell Publishing, Malden, MA
	Tortorella et al., Current Opinion on Investigational Drugs, 2(12), pp. 1751-1756, 2001, published by PharmaPress Ltd., London, GB
	Selby et al., "Safety and Tolerability of Subcutaneous Cladribine Therapy in Progressive Multiple Sclerosis", Can. J. Neurol. Sci., Vol. 25, pp. 295-299, 1998, published by Canadian Journal of Neurological Science, Calgary, Canada
	Rice et al., "Cladribine and progressive MS Clinical and MRI outcomes of a multicenter controlled trial", Neurology, Vol. 54, pp. 1145-1155, 2000, published by Lippincott Williams and Wilkins, Hagerstown, MD
	Lillemark et al., "On the Bioavailability of Oral and Subcutaneous 2-Chloro-2'-Deoxyadenosine in Humans: Alternative Routes of Administration", Journal of Clinical Oncology, Vol. 10, No. 10, pp. 1514-1518, 1992, published by American Society of Clinical Oncology, Alexandria, VA
	Karlsson et al., "Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients", British Journal of Haematology, Vol. 116, pp. 538-548, 2002, published by Blackwell Science Ltd., Oxford, UK
	Lillemark, "The Clinical Pharmacokinetics of Cladribine" Clin. Pharmacokinet, Vol. 32 (2), pp. 120-131, 1997, published by Adis International Limited, Wolters Kluwer Health, Yardley, PA
	Nogradi, "Dimethyl- β -Cyclodextrin", Drugs of the Future, Vol. 9, No. 8, pp. 577-578, 1984, published by JR Prous SA Publishers, Barcelona, Spain
	Nakai et al., "Effects of Grinding on the Physical and Chemical Properties of Crystalline Medicinals with Microcrystalline Cellulose V: Comparison with Tri-O-methyl- β -cyclodextrin Ground Mixtures", Chem. Pharm. Bulletin, Vol. 28(5), pp. 1552-1558, 1980, published by Pharmaceutical Society of Japan, Tokyo, Japan
	Saenger, "Cyclodextrin Inclusion Compounds in Research and Industry", Angew. Chem. Int. Ed. Engl., Vol. 19, pp. 344-362, 1980, published by Verlag Chemie, GmbH, Weinheim, Germany

Examiner Signature	/Nathan Schlientz/	Date Considered	03/16/2010
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.W.S.